Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Hold Annual Meeting of Stockholders
May 10, 2018 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 16, 2018...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
May 01, 2018 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 01, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) and The ALS Association today announced the continuation of their partnership in...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics, Inc. Reports First Quarter 2018 Financial Results
April 26, 2018 16:00 ET | Cytokinetics, Incorporated
Completed Enrollment in Phase 2 Study of Reldesemtiv in Patients with SMA;Data Expected in Q2 2018 Preparing to Initiate Second Phase 3 Clinical Trial of Omecamtiv Mecarbil SOUTH SAN FRANCISCO,...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference
April 24, 2018 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that data from the Phase 2 clinical study of reldesemtiv in patients with...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics to Announce First Quarter Results on April 26, 2018
April 12, 2018 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report first quarter results on April 26, 2018 at...
Cytokinetics.png
Cytokinetics to Present at March Investor Conferences
March 05, 2018 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics.png
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
February 28, 2018 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is joining the global initiative to raise awareness of Rare Disease...
Cytokinetics.png
Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
February 15, 2018 16:00 ET | Cytokinetics, Incorporated
 Company Provides 2018 Financial Guidance and Expected Milestones; Reduced Operating Expenses vs. 2017; Over Two Years of Cash Based on Current Burn Rate CK-2127107 Advancing in Four Clinical Trials...
Cytokinetics.png
Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
February 14, 2018 16:00 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a...
Cytokinetics.png
Cytokinetics Names Robert Califf, M.D., to Board of Directors
February 12, 2018 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that Robert Califf, M.D., has been appointed to the company’s Board of...